A series of local service evaluations to describe the chemotherapy treatment of metastatic hormone refractory prostate cancer (mHRPC)
Prostate cancer is one of the four most common cancers in the UK and is the most common cancer in men in the UK – it accounts for nearly a quarter (24%) of all new male cancer diagnoses1. Prostate cancer tends to develop in men over the age of fifty and although it is one of the most prevalent types of cancer in men it is usually slow-growing and many patients never have symptoms undergo no therapy and eventually die of other causes. Treatment for prostate cancer may involve active surveillance (monitoring for tumor progress or symptoms) surgery (i.e. radical prostatectomy) radiation therapy hormonal therapy chemotherapy or a combination of these treatments depending on tumour stage prognosis and the patients health status. As the growth of most prostate cancers is stimulated by testosterone hormonal therapies that modify levels of or responses to testosterone are standard treatment for men with metastatic disease. Hormonal therapies are initially effective in 80% of men with metastatic prostate cancer but after around 18 months the disease usually becomes unresponsive to hormone treatment (metastatic hormone refractory prostate cancer or mHRPC) and will progress2. Treatment options for those patients with mHRPC are more limited. In June 2006 NICE issued positive guidance on the use of docetaxel (Taxotere) for the treatment of patients with mHRPC and a Karnosky performance status score of > 60% for up to 10 cycles of progression-free treatment2. Despite NICE endorsing the use of docetaxel in this population there is thought to be significant variation in the number of patients receiving docetaxel how it is used and subsequent management of this group of patients across the country. The NHS is required to audit compliance with NICE guidance and is also interested in evaluating the wider management of mHRPC including second and subsequent line chemotherapies in order to inform current practice and promote subsequent service improvements. In recent years there has been an increasing acceptance of the role of second and subsequent line chemotherapy in the management of HRPC however there is currently a lack of evidence as to the regimens used in clinical practice following docetaxel failure.
|PI Name||James - ND|
|Proposed End Date||04/02/2012|
|Study Run through CRF?||No|
|Recruitment so far||0|